Luisa M. Deberle
Villigen, AG 5232, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 20, 2026
Design and Preclinical Evaluation of a Novel Prostate-Specific Membrane Antigen Radioligand Modified with a Transthyretin Binder.
Journal: Cancers
Published: February 16, 2024
Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
Journal: Cancers
Published: July 12, 2023
Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy.
Journal: Molecular pharmaceutics
Published: May 11, 2022
Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.
Journal: Molecular pharmaceutics
Published: February 22, 2022
Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Cancer Radiotheranostics.
Journal: Bioconjugate chemistry
Published: July 12, 2021
Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 17, 2020
Combined Application of Albumin-Binding [177Lu]Lu-PSMA-ALB-56 and Fast-Cleared PSMA Inhibitors: Optimization of the Pharmacokinetics.
Journal: Molecular pharmaceutics
Published: May 09, 2020
Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
Journal: Molecules (Basel, Switzerland)
Published: May 01, 2020
Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates-new perspectives for folate receptor-targeted radionuclide therapy.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 26, 2020
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Journal: Theranostics
Published: September 20, 2019
Last Updated: 09/26/2026